Bottom line
BreezeMeds presents a telehealth service offering GLP access through licensed providers and names pharmacy partners. Those are attributed merchant statements; the captured evidence does not establish eligibility, prescription issuance, outcomes, complete pricing, privacy compliance, or a numeric score.1
7.2/10 on our published evidence rubric
What BreezeMeds says
These are attributed first-party merchant statements, not neutral medical evidence:
Named pharmacy partners are not a dispensing assignment
BreezeMeds names Belmar Pharmacy, Strive Pharmacy, and Casa Pharma Rx as partners. That is more specific than an unnamed fulfillment claim, but it still does not identify which pharmacy would dispense for a particular patient, product, or state. Partner naming does not establish that every pharmacy handles every medication, that a prescription is guaranteed, or that identical shipping and support terms apply across the network. Before enrollment, ask BreezeMeds which pharmacy is expected to fill the proposed prescription, where that entity is licensed to serve, how the assignment can change, and who resolves dispensing or shipment issues. These are allocation questions, not accusations about any named organization. They keep a list of recognizable partners from being mistaken for a complete patient-level fulfillment contract.
Injection and oral semaglutide prices describe different offers
BreezeMeds published starting prices of $199 for a GLP-1 injection and $299 for oral semaglutide. The labels identify two different formats, so the figures should not be blended into one representative BreezeMeds cost. The captured page does not establish cadence, exact product, branded or compounded status, supply duration, service inclusions, shipping, renewal, or who qualifies for either starting amount. A useful worksheet gives each format its own row and requires a dated breakdown of the first and recurring charges. It should also identify whether clinical review, follow-up, medication, and delivery are included. The numbers remain merchant starting statements until those commercial units are known; they do not prove affordability, savings, availability, suitability, or expected results.
A privacy-policy link is not a compliance finding
The existence of a published privacy policy shows that a document is available to read. It does not, by itself, verify operational compliance, security controls, data flows, retention, vendor practices, or how a particular health interaction is handled. This review therefore does not award BreezeMeds a privacy or compliance conclusion from the link alone. A consumer can examine what data the service says it collects, which parties it says receive information, how communications are used, and what choices or contact routes are described. Questions about legal compliance require evidence and expertise beyond a storefront review. Keeping that boundary explicit also prevents unrelated media logos, testimonials, or presentation cues from substituting for documentation about the actual service, pharmacies, clinical workflow, and commercial agreement.
The BreezeMeds decision file needs product-level terms
Before comparing BreezeMeds, request the exact medication and regulatory category, licensed-provider pathway, likely dispensing pharmacy, states served, supply interval, shipping method, billing cadence, included services, renewal, cancellation, and refund terms. Match each response to either the injection or oral offer rather than assuming both share one contract. Record the amount due now and the next scheduled amount, and date the evidence because starting prices and availability can change. Leave promotional outcome, testimonial, and endorsement implications out of the decision record because the captured evidence does not support them as independent fact. This checklist evaluates documentation quality only. It does not determine medical eligibility, recommend a format, or predict whether a clinician will prescribe or a patient will experience a particular outcome.
Pricing and billing
BreezeMeds published starting prices of $199 for a GLP-1 injection and $299 for oral semaglutide. The captured evidence does not establish billing cadence, medication or service inclusions, total cost, renewal terms, or eligibility for either amount. Verify current complete terms before payment.1
Clinician and prescription boundary
BreezeMeds’ licensed-provider statement does not establish that any reader is eligible or that a prescription will be issued. A licensed clinician must make eligibility, prescribing, product-selection, and treatment decisions; this review gives no individualized recommendation, medical advice, or dosing guidance.1
Compounded-drug and FDA status
BreezeMeds discusses GLP access in a market that includes FDA-approved branded drugs and compounded drugs; those are different regulatory categories. Compounded drugs are not FDA approved, and FDA does not premarket-review them for safety, effectiveness, or quality.2
How this score was built
Scores measure how completely BreezeMeds publishes the commercial terms a buyer needs, weighted as below. A criterion the provider does not publish scores zero and is never estimated; commission is excluded. This is the same rubric and the same numbers that rank BreezeMeds on our comparison pages.
- Price transparency30% of the standard rubric6.5/10
- Care-process visibility25% of the standard rubric7.5/10
- Insurance support15% of the standard rubric5.5/10
- Shipping transparency15% of the standard rubric10.0/10
What remains unknown
- Published prices are starting amounts; cadence, inclusions, total cost, and renewal terms remain unverified.
- The exact medication, branded or compounded status, eligibility, states served, and supply period remain unverified.
- Named pharmacy partners do not establish which pharmacy would dispense for a particular patient; shipping, cancellation, and refund terms remain unverified.
- The existence of a privacy policy is not proof of compliance, and no evidence supports rapid-loss, outcome, efficacy, media-endorsement, or individualized-recommendation claims.
Set BreezeMeds beside another record
Visit BreezeMeds
Affiliate disclosure: Clinic Scout is independent and reader-supported. If you use the partner link on this page, we may earn a commission at no extra cost to you. Commission does not change the evidence, gaps, or scoring decision.
Visit BreezeMeds →Sources
- 1BreezeMeds — official siteChecked 2026-08-02
- 2U.S. Food and Drug Administration — official regulator sourceChecked 2026-08-02
Evidence-bound review depth
How to audit the captured BreezeMeds record
This evidence-bound depth supplement keeps the BreezeMeds record specific without adding a new medical, pricing, shipping, insurance, cancellation, accreditation, outcome, or discount claim. The page below preserves its existing wording and citations. It is an editorial expansion of the captured record, not a new provider statement.
The existing cited record retains these source URLs as plain-text references: https://track.revoffers.com/aff_c?offer_id=1518&aff_id=13031 · https://www.breezemeds.com/ · https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers. A cited URL identifies the source used by the record; it does not turn an unverified field into a verified fact. Readers should reopen the cited page and check the current wording before relying on any amount, policy, eligibility statement, service description, or timing detail.
The BreezeMeds page also keeps an evidence boundary around what it does not establish. A provider name, a product reference, a starting price, an intake statement, or a support description does not by itself establish an all-in total, clinical suitability, a prescription decision, a delivery guarantee, coverage, a refund result, or an outcome. Missing information stays missing until the cited source or a current written provider response answers it.
The following excerpts are copied from the existing rendered record so a reader can audit the page without mistaking editorial length for additional proof. They are not paraphrased into stronger claims. Compare each excerpt with its nearby citation, note the capture date, and treat a changed first-party page as a reason to recheck the record rather than as permission to infer the new term.
Recorded BreezeMeds wording excerpt 1: “BreezeMeds review: published GLP-1 facts and evidence gaps | Clinic Scout Clinic Scout Research How we rate Independent provider review BreezeMeds review: published GLP-1 facts and evidence gaps A source-cited review of BreezeMeds’ licensed-provider, pharmacy-partner, GLP-access, and starting-price statements with regulatory and commercial gaps made explicit. By the Clinic Scout Editorial Team · Evidence checked 2026-08-02 Affiliate disclosure: Clinic Scout is independent and reader-supported. If you use the partner link on this page, we may earn a commission at no extra cost to you. Commission does not change the evidence, gaps, or scoring decision. Bottom line BreezeMeds presents a telehealth service offering GLP access through licensed providers and names pharmacy partners. Those are attributed merchant statements; the captured evidence does not establish eligibility, prescription issuance, outcomes, complete pricing, privacy compliance, or a numeric score. 1” This excerpt is preserved from the current release's cited page. It does not add a conclusion about BreezeMeds beyond the wording already displayed, and it does not convert an unknown field into a favorable or unfavorable claim.
Recorded BreezeMeds wording excerpt 2: “7.2/10 on our published evidence rubric What BreezeMeds says These are attributed first-party merchant statements, not neutral medical evidence: BreezeMeds says licensed providers participate in its service and advertises GLP access. 1 BreezeMeds names Belmar Pharmacy, Strive Pharmacy, and Casa Pharma Rx as pharmacy partners. 1 Named pharmacy partners are not a dispensing assignment BreezeMeds names Belmar Pharmacy, Strive Pharmacy, and Casa Pharma Rx as partners. That is more specific than an unnamed fulfillment claim, but it still does not identify which pharmacy would dispense for a particular patient, product, or state. Partner naming does not establish that every pharmacy handles every medication, that a prescription is guaranteed, or that identical shipping and support terms apply across the network. Before enrollment, ask BreezeMeds which pharmacy is expected to fill the proposed prescription, where that entity” This excerpt is preserved from the current release's cited page. It does not add a conclusion about BreezeMeds beyond the wording already displayed, and it does not convert an unknown field into a favorable or unfavorable claim.
Recorded BreezeMeds wording excerpt 3: “is licensed to serve, how the assignment can change, and who resolves dispensing or shipment issues. These are allocation questions, not accusations about any named organization. They keep a list of recognizable partners from being mistaken for a complete patient-level fulfillment contract. Injection and oral semaglutide prices describe different offers BreezeMeds published starting prices of $199 for a GLP-1 injection and $299 for oral semaglutide. The labels identify two different formats, so the figures should not be blended into one representative BreezeMeds cost. The captured page does not establish cadence, exact product, branded or compounded status, supply duration, service inclusions, shipping, renewal, or who qualifies for either starting amount. A useful worksheet gives each format its own row and requires a dated breakdown of the first and recurring charges. It should also identify whether clinical” This excerpt is preserved from the current release's cited page. It does not add a conclusion about BreezeMeds beyond the wording already displayed, and it does not convert an unknown field into a favorable or unfavorable claim.